Ivacaftor for patients with cystic fibrosis

References

• Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-9
   PubMed Web of Science ®Google Scholar
• LeGrys VA, Yankaskas JR, Quittell LM, et al. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 2007;151(1):85-9
   PubMedGoogle Scholar
• Gibson R, Burns J, Ramsey B. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8):918-51
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182(5):627-32
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46(4):393-400
   PubMed Web of Science ®Google Scholar
• Byrnes CA, Vidmar S, Cheney JL, et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013;68(7):643-51
   PubMed Web of Science ®Google Scholar
• CFTR2. Available from: http://cftr2.org
   Google Scholar
• Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations – correlation with incidence data and application to screening. Hum Mutat 2002;19(6):575-606
   PubMed Web of Science ®Google Scholar
• Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995;83(1):121-7
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106(44):18825-30
   PubMed Web of Science ®Google Scholar
• Illek B, Zhang L, Lewis NC, et al. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999;277(4 Pt 1):C833-9
   PubMedGoogle Scholar
• Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290(6):L1117-30
   PubMed Web of Science ®Google Scholar
• Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012;11(3):237-45
   PubMed Web of Science ®Google Scholar
• Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 2012;287(44):36639-49
   PubMed Web of Science ®Google Scholar
• Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA 2013;110(11):4404-9
   PubMed Web of Science ®Google Scholar
• Char JE, Wolfe MH, Cho HJ, et al. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. PLoS One 2014;9(2):e88564
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-72
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646-9
   PubMed Web of Science ®Google Scholar
• Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187(11):1219-25
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363(21):1991-2003
   PubMed Web of Science ®Google Scholar
• Quittner AL, Buu A, Messer MA, et al. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128(4):2347-54
   PubMed Web of Science ®Google Scholar
• Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-18
   PubMed Web of Science ®Google Scholar
• McKone E, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the G551D-CFTR mutation:response through 144 weeks of treatment (96 weeks of PERSIST). Pediatr Pulmonol 2013;48(S36):227
   Google Scholar
• Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142(3):718-24
   PubMed Web of Science ®Google Scholar
• Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67(1):12-18
   PubMed Web of Science ®Google Scholar
• Boyle MP, Bell S, Konstan M, et al. The Investigational CFTR corrector, VX-809 (Lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508del homozygous patients: Phase II study results. Pediatr Pulmonol 2012(Suppl 35)):315
   Google Scholar
• Polenakovik HM, Sanville B. The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (DeltaF508/G551D). J Cyst Fibros 2013;12(5):530-1
   PubMedGoogle Scholar
• Barry PJ, Plant BJ, Nair A, et al. Effects of ivacaftor in cystic fibrosis patients carrying the G551D mutation with severe lung disease. Chest 2014;146(1):152-8
   PubMed Web of Science ®Google Scholar
• FDA. Available from: www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm290088.htm
   Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372(9640):719-27
   PubMed Web of Science ®Google Scholar
• Xue X, Mutyam V, Tang L, et al. Synthetic aminoglycosides efficiently suppress CFTR nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol 2014;50(4):805-16
   PubMed Web of Science ®Google Scholar
• Bellin MD, Laguna T, Leschyshyn J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013;14(6):417-21
   PubMed Web of Science ®Google Scholar
• Sloane PA, Shastry S, Wilhelm A, et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 2012;7(6):e39809
   PubMedGoogle Scholar